Financial Analysis: Immunovant Inc (IMVT)’s Ratios Unveil Key Insights

Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

As of close of business last night, Immunovant Inc’s stock clocked out at $30.02, up 1.38% from its previous closing price of $29.61. In other words, the price has increased by $1.38 from its previous closing price. On the day, 0.51 million shares were traded. IMVT stock price reached its highest trading level at $30.08 during the session, while it also had its lowest trading level at $29.24.

Ratios:

To gain a deeper understanding of IMVT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.08 and its Current Ratio is at 13.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on Oct-10-24, Reiterated its Outperform rating but revised its target price to $53 from $47 previously.

On March 28, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $50.

On March 13, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $50.Goldman initiated its Buy rating on March 13, 2024, with a $50 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 21 ’24 when Levine Mark S. sold 3,295 shares for $31.86 per share. The transaction valued at 104,976 led to the insider holds 330,099 shares of the business.

Macias William L. sold 3,027 shares of IMVT for $96,437 on Aug 21 ’24. The Chief Medical Officer now owns 368,332 shares after completing the transaction at $31.86 per share. On Aug 21 ’24, another insider, Barnett Eva Renee, who serves as the Chief Financial Officer of the company, sold 3,768 shares for $31.86 each. As a result, the insider received 120,045 and left with 343,776 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMVT now has a Market Capitalization of 4393937408 and an Enterprise Value of 3834012672.

Stock Price History:

Over the past 52 weeks, IMVT has reached a high of $45.58, while it has fallen to a 52-week low of $24.67. The 50-Day Moving Average of the stock is 0.60%, while the 200-Day Moving Average is calculated to be -5.08%.

Shares Statistics:

It appears that IMVT traded 982.19K shares on average per day over the past three months and 633480 shares per day over the past ten days. A total of 145.58M shares are outstanding, with a floating share count of 62.01M. Insiders hold about 57.63% of the company’s shares, while institutions hold 50.59% stake in the company. Shares short for IMVT as of 1726185600 were 12458767 with a Short Ratio of 12.68, compared to 1723680000 on 12231170. Therefore, it implies a Short% of Shares Outstanding of 12458767 and a Short% of Float of 19.469998999999998.

Most Popular